Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

Nov 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results ...

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...